VistaGen Therapeutics, Inc. (VTGN:NASDAQ) rocketted at $0.19, representing a gain of 23.1%. On Wed, Aug 17, 2022, VTGN:NASDAQ hit a New 2-Week High of $0.19. The stock appeared on our News Catalysts scanner on Thu, Aug 11, 2022 at 06:16 PM in the 'INVESTOR UPDATE' category. From Wed, Aug 03, 2022, the stock recorded 40.00% Up Days and 36.36% Green Days
The stock spiked on Thu, Jul 21, 2022 at $1.07 with a volume of 3M+.
About VistaGen Therapeutics, Inc. (VTGN:NASDAQ)
VistaGen Therapeutics Inc is a clinical-stage biopharmaceutical company that develops and commercializes product candidates for patients with central nervous system diseases. Its product AV-101 is currently being evaluated in a Phase 2 monotherapy study.
Top 10 Gainers:
- Blue Water Vaccines Inc. (BWV:NASDAQ), 199.61%
- Hill International, Inc. (HIL:NYSE), 60.34%
- Eargo Inc. (EAR:NASDAQ), 54.95%
- Nova LifeStyle, Inc. (NVFY:NASDAQ), 42.31%
- TDH Holdings, Inc. (PETZ:NASDAQ), 38.31%
- Cassava Sciences, Inc. (SAVA:NASDAQ), 27.26%
- Regis Corporation (RGS:NYSE), 24.17%
- VistaGen Therapeutics, Inc. (VTGN:NASDAQ), 23.07%
- Vinco Ventures Inc. (BBIG:NASDAQ), 23.01%
- Laird Superfood Inc. (LSF:NYSEMKT), 22.67%